Other Stories

Experts advise drug ministry to grant conditional use permit for Celltrion's COVID-19 treatment Updated: 2021-01-18 15:26:46 KST

A panel of experts have recommended that the Ministry of Food and Drug Safety grant conditional use authorization to the South Korean pharmaceutical giant Celltrion for its COVID-19 treatment candidate.
That'll enable the drug to be used more generally in South Korea and to export it to other countries.
Celltrion is working on a monoclonal antibody treatment called CT-P59, also known as Regdanvimab.
The ministry said Monday it was advised to give the go-ahead on the condition that the drug goes through another, third trial.
Clinical data so far show the drug can shorten COVID-19 recovery times by almost 3-and-a-half days.
But in terms of how long it takes to test negative, it did not show any significant effect.
Reporter : jhee@arirang.com
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.